Most recent articles by:

Oliver Schacht

Oliver Schacht is the CEO of OpGen, Inc., a pioneering precision medicine, bioinformatics and genomic analysis company providing complete solutions for patients, hospitals, and network-wide infection prevention and treatment decisions.
- Advertisement -

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC
- Advertisement -